These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38229750)

  • 1. Discovery of Novel PDEδ Autophagic Degraders: A Case Study of Autophagy-Tethering Compound (ATTEC).
    Bao J; Chen Z; Li Y; Chen L; Wang W; Sheng C; Dong G
    ACS Med Chem Lett; 2024 Jan; 15(1):29-35. PubMed ID: 38229750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydrophobic Tagging-Induced Degradation of PDEδ in Colon Cancer Cells.
    Guo M; He S; Cheng J; Li Y; Dong G; Sheng C
    ACS Med Chem Lett; 2022 Feb; 13(2):298-303. PubMed ID: 35178186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer.
    Cheng J; Li Y; Wang X; Dong G; Sheng C
    J Med Chem; 2020 Jul; 63(14):7892-7905. PubMed ID: 32603594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ispinesib as an Effective Warhead for the Design of Autophagosome-Tethering Chimeras: Discovery of Potent Degraders of Nicotinamide Phosphoribosyltransferase (NAMPT).
    Dong G; Wu Y; Cheng J; Chen L; Liu R; Ding Y; Wu S; Ma J; Sheng C
    J Med Chem; 2022 Jun; 65(11):7619-7628. PubMed ID: 35588495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research.
    Li X; Liu Q; Xie X; Peng C; Pang Q; Liu B; Han B
    J Med Chem; 2023 Feb; 66(3):1700-1711. PubMed ID: 36716420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting lipid droplets for autophagic degradation by ATTEC.
    Fu Y; Lu B
    Autophagy; 2021 Dec; 17(12):4486-4488. PubMed ID: 34436975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioorthogonal Aptamer-ATTEC Conjugates for Degradation of Alpha-Synuclein via Autophagy-Lysosomal Pathway.
    Liao X; Qin G; Liu Z; Ren J; Qu X
    Small; 2024 Feb; 20(8):e2306760. PubMed ID: 37821404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel KRAS‒PDE
    Chen L; Zhang J; Wang X; Li Y; Zhou L; Lu X; Dong G; Sheng C
    Acta Pharm Sin B; 2022 Jan; 12(1):274-290. PubMed ID: 35127385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells.
    Chen YH; Lv H; Shen N; Wang XM; Tang S; Xiong B; Ding J; Geng MY; Huang M
    Acta Pharmacol Sin; 2020 Feb; 41(2):270-277. PubMed ID: 31316177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted clearance of mitochondria by an autophagy-tethering compound (ATTEC) and its potential therapeutic effects.
    Tan S; Wang D; Fu Y; Zheng H; Liu Y; Lu B
    Sci Bull (Beijing); 2023 Dec; 68(23):3013-3026. PubMed ID: 37940449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based development of PDEδ inhibitors.
    Martín-Gago P; Fansa EK; Wittinghofer A; Waldmann H
    Biol Chem; 2017 May; 398(5-6):535-545. PubMed ID: 27935847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancing targeted protein degradation for metabolic diseases therapy.
    Zhou QQ; Xiao HT; Yang F; Wang YD; Li P; Zheng ZG
    Pharmacol Res; 2023 Feb; 188():106627. PubMed ID: 36566001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer.
    Leung EL; Luo LX; Li Y; Liu ZQ; Li LL; Shi DF; Xie Y; Huang M; Lu LL; Duan FG; Huang JM; Fan XX; Yuan ZW; Ding J; Yao XJ; Ward DC; Liu L
    Int J Cancer; 2019 Sep; 145(5):1334-1345. PubMed ID: 30786019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of PD3 and PD3-B for PDEδ inhibition to modulate KRAS activity.
    Lee J; Lee HJ; Lee Y; Lim B; Gam J; Oh DC; Lee J
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1656-1666. PubMed ID: 35695156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Novel KRAS-PDEδ Inhibitors by Fragment-Based Drug Design.
    Chen L; Zhuang C; Lu J; Jiang Y; Sheng C
    J Med Chem; 2018 Mar; 61(6):2604-2610. PubMed ID: 29510040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a PDEδ-Targeting PROTACs that Impair Lipid Metabolism.
    Winzker M; Friese A; Koch U; Janning P; Ziegler S; Waldmann H
    Angew Chem Int Ed Engl; 2020 Mar; 59(14):5595-5601. PubMed ID: 31829492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking the Farnesyl Pocket of PDEδ Reduces Rheb-Dependent mTORC1 Activation and Survival of
    Armijo ME; Escalona E; Peña D; Farias A; Morin V; Baumann M; Klebl BM; Pincheira R; Castro AF
    Front Pharmacol; 2022; 13():912688. PubMed ID: 35814251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel PDEδ interacting proteins.
    Küchler P; Zimmermann G; Winzker M; Janning P; Waldmann H; Ziegler S
    Bioorg Med Chem; 2018 May; 26(8):1426-1434. PubMed ID: 28935183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas.
    Klein CH; Truxius DC; Vogel HA; Harizanova J; Murarka S; Martín-Gago P; Bastiaens PIH
    Int J Cancer; 2019 Feb; 144(4):767-776. PubMed ID: 30194764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.